【Abstract】Objective To investigate the efficacy of rosuvastatin in the prevention of carotid restenosis after carotid artery stenting (CAS). Methods Sixty-nine patients who had undergone CAS in our hospital from March 2014 to August 2015 were recruited prospectively, and then randomly assigned to the control group (n=34, bayaspirin 100 mg/d) and treatment group (n=35, bayaspirin 100 mg/d and clopidogrel 75 mg/d). After oral administration for 12 months, the therapeutic effects were compared between the 2 groups. SPPS statisitics 17.0 was used. The data were analyzed by t test, variance analysis, or Chi-square test. Results At 12 months post-CAS, repeated CT angiography showed that the treatment group was superior to the control group in stent smoothness, stent inner diameter, as well as the vascular conditions at the proximal and distal ends of the stent (P<0.01), and in lower stent lumen density and stent restenosis rate (P<0.01). In the treatment group, the levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) were significantly decreased (P<0.01), while that of adiponectin (APN) was obviously increased after the treatment (P<0.01). However, no changes were found in the levels of TC, LDL-C, or APN in the control group (P>0.05). Conclusion Oral administration of rosuvastatin exerts significant effect on the prevention of post-CAS in-stent restenosis and occlusion, and thus reduces the restenosis rate.
